Hollister brings 25+ years of financial leadership across the global semiconductor industry, including previous CFO roles at GlobalFoundries and Silicon Labs

SYDNEY, Sept. 16, 2026 /PRNewswire/ — Silicon Quantum Computing (SQC), a pioneer in quantum computing and atomic-precision manufacturing, today announced the appointment of John Hollister as Chief Financial Officer, effective 17 August 2026. Hollister will lead global financial strategy and operations as SQC advances its roadmap to universal, commercial-scale quantum computers.

Based in the U.S., Hollister is a global finance executive with more than two decades of leadership experience within the semiconductor industry. He has led and scaled international teams through periods of accelerated growth, with expertise spanning capital formation, financial planning and analysis, worldwide accounting, financial reporting, M&A, tax and investor relations.

Prior to SQC, Hollister served as CFO at GlobalFoundries, one of the world’s largest semiconductor foundries. Earlier in his career, he spent two decades at Silicon Labs, including 11 years as the company’s CFO, and held previous roles at Cicada Semiconductor and Cirrus Logic.

SQC Founder and CEO, Michelle Simmons, said: “Building a globally competitive quantum computing company requires the sharpest minds and deep knowledge. John brings a track record of financial rigor and expertise that is critical to advancing our commercial roadmap and scaling our world-leading manufacturing technology. We are delighted to have him on board.”

SQC Chief Financial Officer, John Hollister, added: “I look forward to building the financial infrastructure to support SQC’s next phase of growth, both in Australia and globally. Bringing quantum computing to the world is a massive opportunity, and SQC’s atomic-precision manufacturing capability gives us a distinct commercial and scientific advantage.”

Hollister’s arrival follows the appointment of Karna Nisewaner as Chief Legal Officer in June 2026. Together, these appointments bolster SQC’s executive leadership with decades of expertise building and running the operational machine behind chip design and manufacturing. SQC is one of 11 companies selected for Stage B of DARPA’s Quantum Benchmarking Initiative, and the company continues to deploy its quantum-enhanced AI and materials simulation chips to customers today.

For more information, visit www.sqc.com and follow SQC on LinkedIn.

About Silicon Quantum Computing

Silicon Quantum Computing (SQC) is at the forefront of global efforts to deliver a commercial-scale quantum system. Backed by 25 years of technological leadership, SQC holds a singular advantage: exclusive capability to manufacture silicon chips with atomic precision, enabling quantum computing systems with world-leading algorithmic fidelity. With in-house QPU manufacturing, SQC iterates new chips weekly while delivering quantum-enhanced AI and materials simulation systems to customers today. The company was founded in 2017 and is headquartered in Sydney, Australia.

Media Contact
press@sqc.com

PARIS, Sept. 16, 2026 /PRNewswire/ — Kongsberg Satellite Services (KSAT), a leading provider of ground station networks and satellite operations, announced that KSAT was selected by Intuitive Machines to support NASA’s EAGLE (Explorer for Artemis Geology, Lunar, and Earth) VSWIR Mission, currently scheduled to launch in 2028.

KSAT will operate the IM 300 spacecraft, which will integrate the NASA Jet Propulsion Laboratory (JPL)’s Visible to Shortwave Infrared (VSWIR) instrument to characterize Earth’s surface by investigating ground and water temperature, snow reflectivity, active geologic processes, vegetation traits, and algal biomass. The mission also tests technology that could support future lunar and Mars exploration. Under the partnership between NASA, Intuitive Machines, and KSAT, KSAT will provide its streamlined Integrated Mission Services, inclusive of global ground station services and satellite operations services.

“KSAT is thrilled to support NASA in science and exploration. In partnership with Intuitive Machines, we are eager to provide NASA with mature commercial solutions with predictable costs. We look forward to our continued support for NASA’s mission and their vision of space exploration,” said Dan Adams, General Manager of KSAT Inc.

“Our partnership with KSAT is a critical component of delivering mission success for NASA JPL’s EAGLE-VSWIR mission. By combining Intuitive Machines’ spacecraft and mission integration capabilities with KSAT’s global ground station network and operational expertise, we are confident we can deliver resilient end-to-end services for the successful mission,” said Rizwan Parvez, Senior Director, Business Development at Intuitive Machines.

About KSAT:

Kongsberg Satellite Services (KSAT) is the leading provider of Ground Station Services, Earth Observation Services, and Satellite Operations Services. Headquartered in Tromsø, Norway, the company operates the largest commercial satellite ground station network worldwide, including facilities in Svalbard and Antarctica to provide unique southern hemisphere coverage. Through KSAT Inc., KSAT’s U.S.-based, full-capability subsidiary in Denver, Colorado, delivers mission-critical infrastructure for customers in government, civil, and commercial space in the United States, as well as the global space industry.

Media Contact:
mediacontact@ksat.no

• Rosewood Hong Kong (No.1) has once again been named The World’s Best Hotel 2026
• The list celebrates hotels from 22 destinations across six continents, with Europe leading the way with 21 winning hotels
• Chablé Yucatán (No.9) in Mexico wins the Bombay Sapphire Eco Hotel Award, audited by the Sustainable Restaurant Association
• In its second year, the Johnnie Walker Art of Design Award is presented to Hôtel du Couvent (No.38) in Nice, France
• James McBride, founder of Nihi Hotels, is celebrated with the SevenRooms Icon Award
• The Best Boutique Hotel Award is awarded to Passalacqua (No.5) in Lake Como, for a third year
• Patina Osaka in Japan (No.33) wins the Nikka Best New Hotel Award
• Other accolades include Ferrari Trento Most Admired Hotel Group Award, awarded to Rosewood; WhistlePig Highest Climber Award goes to Las Ventanas al Paraíso (No.25) in Los Cabos, Mexico; Casa Maria Luigia (No.18) in Modena, Italy wins the Lavazza Highest New Entry Award; and the Best Beach Hotel Award goes to Atlantis The Royal (No.4) in Dubai
• The Fifth Avenue Hotel (No.78) in New York City received the American Express Travel One to Watch Award and Switzerland’s Badrutt’s Palace (No.36) was honoured with the SeiBellissimi Art of Hospitality Award

PARIS, Sept. 15, 2026 /PRNewswire/ — The list of The 50 Best Hotels has been revealed at a prestigious awards ceremony in Paris. The unveiling recognises exceptional and pioneering hospitality experiences from across the globe.

See the full list of The 50 Best Hotels 2026 here

Rosewood Hong Kong (No.1) has once again been recognised as The World’s Best Hotel, following its ranking as No.1 in 2025 and No.3 in 2024. The No.2 spot goes to Capella Bangkok and Four Seasons Bangkok at Chao Phraya River ranks at No.3. Asia has 18 hotels including four in Japan: Aman Tokyo (No.11), Bulgari Tokyo (No.24), Patina Osaka (No.33) and Park Hyatt Kyoto (No.37).

Europe leads the way with 21 winning hotels, including six in Italy and France, four in the UK and one in Greece, Monaco, Switzerland and Türkiye. The highest-ranking European entry is Passalacqua (No.5) in Lake Como.

North America lists six properties and South America has two hotels. Oceania has one hotel included, whereas Africa is home to two.

Media Contact: The50BestHotels@thesaucecollective.com

Media Centre: https://mediacentre.the50.com/ 

Designed for the way today’s youth create—anytime, anywhere, across any medium

SHENZHEN, China, Sept. 16, 2026 /PRNewswire/ — ugee, one of the leading digital hardware and software developers, announced the launch of ArtPlay Pad, a groundbreaking creative tablet tailored for young beginner creators and kids. Departing from one-size-fits-all adult-oriented devices, ArtPlay Pad reimagines the drawing tablet as a portable studio that turns doodles into dimensional designs. It includes a lifetime ibisPaint license, integration with Tripo AI for turning 2D sketches into 3D models, professional EMR pen technology delivering an authentic pen-on-paper feel, and a display with TÜV SÜD Low Blue Light Certification and AG-etched glass anti-glare for eye protection, more comfortable creative sessions.

“With the rapid advancement of creative tools in both hardware and software sciences, the younger generation has increasingly higher demands for diverse and varied forms of creative expression. Unlike most children’s tablets that use capacitive pen technology, ugee has long focused on EMR pressure-sensitive pen technology for professional creatives, delivering a tactile pen-on-paper feel. Now we are applying this to serve children and DIY creators with a product that enables both paper-like drawing and digital software creation,” said Amy Yuan, Global Brand Director of ugee.

“The ArtPlay Pad features EMR pen technology, broad software compatibility, and AG-etched glass anti-glare for eye health. We want creation to go beyond the mind—so imagination can be truly seen and touched. That is the original intention behind this product, designed to tackle three core challenges: the stroke barrier for a natural writing feel, the 2D-to-3D creative gap to keep the process engaging, and eye-care protection for healthier usage,” she added.

Stroke Barrier — Glass screens feel slick and unresponsive, often discouraging beginners before they begin.

ArtPlay Pad counters this with 16K ultra-sensitive pressure powered by smart chip, and advanced EMR (Electro-Magnetic Resonance) technology, paired with a paper-like anti-glare display and full palm rejection.The result: tactile friction that mirrors pencil on paper, preserving muscle memory and transforming the first stroke from a stumbling block into a confident start. And with access to a vast library of creative and educational apps via Google Play, young creators can explore endless possibilities—from digital painting and 3D modeling to animation and interactive learning—all at their fingertips.

2D-to-3D Barrier — Today’s young creators think in volume and space, not just lines.

ArtPlay Pad breaks this barrier with a seamless workflow, powered by deeply integrated ibisPaint (ad-free education version with lifetime access) and Tripo AI. With a single tap, AI converts flat sketches into fully realized 3D models—not cold renders, but living extensions of the original drawing. Models can be exported directly to the ugee Funbox 3D Printer, turning digital designs into tangible creations. This end-to-end workflow embeds STEM learning at every step—from spatial reasoning during modeling to engineering principles during printing. Beyond creative play, 3D design helps children tackle school projects—building historical models, visualizing science concepts, or prototyping inventions—and even create practical tools like phone stands or organizers to help parents at home.

Eye-Care Barrier — Parents worry not just about how long kids stare at screens, but what it does to their eyes.

ArtPlay Pad shifts the conversation from duration to depth. The 12″ 2K Eye-Care Display features a 16:9 aspect ratio, 16.7 million colors, full lamination, and anti-glare + anti-fingerprint coating—delivering vivid visuals indoors and out. With TÜV SÜD Low Blue Light Certification and AG-etched glass anti-glare technology, prolonged use causes less eye strain without compromising color accuracy, while reducing distracting reflections for a more comfortable viewing experience.

Premium Hardware That Powers Infinite Creativity

Packed with high-performance hardware, the ArtPlay Pad fuels non-stop creativity. It features 6GB RAM + 256GB expandable storage, holding 50,000+ sketches and hundreds of 3D models. The 7800 mAh battery delivers up to 18 hours of drawing or 12 hours of video playback with 30W fast charging, while the MediaTek Helio G99 octa-core chip ensures smooth performance across 3D tools, education apps, and HD videos. Immersive 360° quad-speaker audio, crisp 13MP rear and 8MP front cameras for calls and photo sharing, and an included adjustable silicone case with a stepless stand and stylus slot complete the experience. At just 7.4mm thin and 644g light, this slim tablet goes wherever inspiration takes you.

Launch and Availability

ArtPlay Pad is available starting September 15, 2026—timed to inspire young creators and reassure parents alike. The device comes with a suite of pre-installed creative apps, cloud-based sharing capabilities, and a protective case designed for on-the-go inspiration. Order now at the ugee official shop to bring home the ultimate creative companion for your child.

About ugee

A global creative hardware enterprise distributing products across 100+ nations, ugee focuses on digital art equipment and educational STEM tools, extending its layout from drawing tablets to household 3D printing to fuel children’s hands-on creativity.

• The fifteen-month dataset represents the final analysis from the Phase 1/2 study
• At the Month 15 primary timepoint, SKY-0515-treated patients showed a +1.59-point difference in Composite Unified Huntington’s Disease Rating Scale (cUHDRS) change from baseline versus overlap-weighted external natural history control
• Differences favoring SKY-0515 were statistically significant across all four cUHDRS components – Total Functional Capacity, Total Motor Score, Symbol Digit Modalities Test and Stroop Word Reading Test – and cUHDRS differences favored SKY-0515 at every prespecified timepoint in the study
• SKY-0515 has shown consistent average reductions in mutant huntingtin protein (mHTT) throughout the study of more than 60% at the 9 mg dose  
• SKY-0515 has shown consistent average reductions in PMS1 mRNA of more than 25% at the 9 mg dose
• The Company’s Phase 1/2 program and global Phase 2/3 FALCON-HD 004-ANZ + 004-WW pivotal program for Huntington’s disease now have enrolled over 200 patients across twenty trial sites in ten countries.

BOSTON, Sept. 16, 2026 /PRNewswire/ — Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced final fifteen-month results from its Phase 1/2 clinical trial evaluating SKY-0515, an investigational oral treatment for Huntington’s disease (HD).

The Phase 1/2 patient study is a randomized, double-blind, placebo-controlled parallel-group study evaluating two dose levels of SKY-0515 in patients over twelve weeks, followed by a twelve-month blinded Extension period during which all participants receive active treatment at either a low or high dose (4mg or 9mg), with the majority of patients on the 9 mg dose.

At Month 15, the primary timepoint, patients treated with SKY-0515 improved on the cUHDRS by an average of 0.94 points from where they started, while a comparison group of untreated patients from the Enroll-HD natural history database declined by an average of 0.65 points. The gap between the two groups was 1.59 points (95% CI: 1.09, 2.09; p<0.001).

SKY-0515 patients also did better than the comparison group on each of the four measures that make up the cUHDRS: daily function (Total Functional Capacity, +0.98 points), movement (Total Motor Score, −9.38 points, where a lower score is better), processing speed (Symbol Digit Modalities Test, +4.15 points) and reading speed (Stroop Word Reading Test, +4.18 points). All differences were statistically significant.

Table 1. Change from baseline at Month 15 in cUHDRS and its components, SKY-0515 versus overlap-weighted external control

CI = confidence interval; SE = standard error.

The same pattern held throughout the study. At every scheduled checkpoint, SKY-0515 patients were doing better on the cUHDRS than the comparison group: 0.66 points at Month 3, 0.78 points at Month 6, 1.04 points at Month 9, 0.79 points at Month 12 and 1.59 points at Month 15. The difference was statistically significant from Month 9 onward.

On average, SKY-0515-treated patients’ cUHDRS scores held at or above their baseline level at every assessment through Month 15, while the external comparison group’s average score declined from Month 6 onward.

Table 2. Change from baseline in cUHDRS by timepoint, SKY-0515 versus overlap-weighted external control

CI = confidence interval; SE = standard error. See footnote¹ for data analysis discussion.

SKY-0515 has shown consistent average reductions of more than 60% mutant huntingtin protein (mHTT) and 25% PMS1 mRNA in patients at the 9 mg dose throughout the study. Mutant huntingtin is the primary protein responsible for HD pathology, while PMS1 is a key driver of somatic CAG repeat expansion associated with disease progression.

SKY-0515 has demonstrated excellent central nervous system exposure and has been generally well tolerated across all dose levels studied through fifteen months of treatment, with no treatment-related SAEs. 

“Skyhawk’s Phase 1/2 results are extremely encouraging clinical data. A 1.59-point cUHDRS difference versus a rigorously weighted natural history control at fifteen months is exactly the type of signal the field looks for in early studies of a potentially effective therapeutic agent. The consistent effects on function, motor and cognitive measures need to be further studied in ongoing placebo-controlled studies but it is an exciting step forward for HD and the program,” said Dr. Samuel Frank, Director of the Huntington’s Disease Society of America Center of Excellence at Beth Israel Deaconess Medical Center. “SKY-0515’s dual reduction of mHTT and PMS1 addresses two core pathogenic mechanisms of Huntington’s disease. If these findings are confirmed in the ongoing Phase 2/3 FALCON-HD pivotal program, the impact on people living with HD across the world could be profound.”

“For almost two decades, I have fought as an advocate for Huntington’s disease patients, bearing witness to countless heartbreaking trial setbacks that have let our families down. To finally see results like these—patients experiencing improvements in function, movement, and cognition — is what we have been hoping and waiting for,” said Katie Jackson, Chief Executive Officer of Help 4 HD International. “What makes SKY-0515 especially exciting is that it is a pill, taken once a day at home. Every step forward in HD matters and we celebrate all of them, but a therapy that is noninvasive and does not require care in a specialized center has the potential to reach so many more patients – in rural communities, in families who can’t travel, and across the world where care is hard to come by.

My husband didn’t get a treatment in time. I am hopeful that my children and the children of thousands of families like ours will. We are the generation of change, and Skyhawk’s drug, if these promising results are fully confirmed in future trials, is what change looks like.”

“The completion of this Phase 1/2 study with SKY-0515, showing statistically significant clinical benefit across every cUHDRS component, is a powerful demonstration of what Skyhawk’s SKYSTAR^® platform can achieve: a daily pill, taken at home, that modifies RNA splicing to lower disease-causing proteins in the CNS and systemically throughout the body,” said Sergey Pauskin, Co-founder and Head of R&D at Skyhawk. “We are applying the same platform to a series of challenging neurological diseases now advancing toward human trials, and the data from SKY-0515 confirms that the possibilities of extraordinary novel drugs generated by Skyhawk’s SKYSTAR platform are very exciting.”

Huntington’s disease is a rare, hereditary, and ultimately fatal neurodegenerative disorder affecting more than 40,000 symptomatic individuals in the United States, with hundreds of thousands impacted worldwide. There are currently no approved therapies shown to slow or halt disease progression.

SKY-0515 is an orally administered investigational small molecule RNA splicing modifier developed using the company’s proprietary SKYSTAR platform. SKY-0515 is designed to reduce both mHTT and PMS1 proteins.

The worldwide Phase 2/3 FALCON-HD-004-WW pivotal study is now active across more than ten countries and twenty clinical sites. SKY-0515’s Phase 1/2 and FALCON-HD pivotal studies have now enrolled more than 200 patients.

Skyhawk expects to advance additional novel therapies targeting rare neurological diseases with no approved disease-modifying treatment into clinical development by the end of 2027.

About the Fifteen-Month Analysis
Phase 1/2 cUHDRS LS mean change from baseline versus external control at 3, 6, 9, 12 and 15 months, and cUHDRS subcomponents LS mean change from baseline versus external control at 15 months, were estimated via overlap-weighted ANCOVA for patients receiving SKY-0515 once daily. Nominal timepoints are anchored to a participant’s first dose of SKY-0515 (Day 1 to Month 3: n=24, Month 6: n=20, Month 9: n=20, Month 12: n=18, Month 15: n=15). Overlap-weighted propensity score weighting was performed using Enroll-HD, 2CARE and CREST-E datasets (Month 3: n=21, Month 6: n=180, Month 9: n=588, Month 12: n=3569, Month 15: n=1337).

Participants received placebo, 3 mg or 9 mg during the first 3 months; afterwards, all participants received 4 mg or 9 mg following Extension-phase randomization. The Month 15 decline in participants partly reflects study design, as the 12-month Extension period caps SKY-0515 exposure at 12 months for participants who initially received 3 months of placebo.

The primary analysis includes all eligible participants with an available Month 15 cUHDRS assessment. Per the study’s statistical analysis plan, a small number of participant-timepoints were excluded following a qualifying intercurrent event — onset of an unrelated medical condition, initiation of a medication that could confound assessment of treatment effect, or a change in background Huntington’s disease therapeutic intervention.

About SKY-0515’s Phase 1/2 Clinical Program
SKY-0515’s Phase 1/2 clinical trial is a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKY-0515 in healthy volunteers and patients with early-stage Huntington’s disease (HD).

The trial consists of three parts. Parts A and B evaluated SKY-0515 in Healthy Volunteers. Part C is a randomized, double-blind, placebo-controlled parallel-group study evaluating two dose levels of SKY-0515 in patients with early-stage HD (HD-ISS Stage 1, Stage 2, or mild Stage 3) over 84 days, followed by a twelve-month blinded Extension period during which all participants receive active treatment at either a low or high dose.

Study assessments include measurements of mutant HTT protein, PMS1 mRNA, and cUHDRS.  Enrollment and treatment in the Phase 1/2 study are complete, and the fifteen-month analysis represents the final clinical dataset from the study.

About SKY-0515’s Phase 2/3 FALCON-HD (004-ANZ and 004-WW) Pivotal Program
The FALCON-HD pivotal program (NCT06873334 and NCT07378644) is a randomized, double-blind, placebo-controlled, dose-ranging study evaluating the pharmacodynamics, safety and efficacy of SKY-0515. Eligible patients receive once-daily oral SKY-0515 at one of three dose levels or placebo.

FALCON-HD 004-ANZ enrolled 144 participants with Stage 2 and Stage 3 HD across sites in Australia and New Zealand. Enrollment is complete.

FALCON-HD 004-WW plans to enroll approximately 600 participants with Stage 2 and Stage 3 HD across more than 40 sites worldwide and is actively recruiting.

Additional information regarding FALCON-HD, including participating sites and eligibility criteria, is available at ClinicalTrials.gov and www.FALCON-HD.com.

About Skyhawk Therapeutics
Skyhawk Therapeutics is a clinical-stage biotechnology company leveraging its proprietary SKYSTAR^® platform to discover and develop small molecule RNA-modulating therapies for the world’s most intractable diseases. For more information, visit www.skyhawktx.com.

Skyhawk Contact
Maura McCarthy
Head of Corporate Development
maura@skyhawktx.com 

¹Phase 1/2 cUHDRS LS mean change from baseline vs. external control at 3, 6, 9, 12 and 15 months, estimated via overlap-weighted ANCOVA, for patients receiving SKY-0515 once-daily. Nominal timepoints are anchored to each participant’s first dose of SKY-0515 (Day 1 to Month 3: n=24, Month 6: n=20, Month 9: n=20, Month 12: n=18, Month 15: n=15). Participants received placebo, 3 mg or 9 mg during the first 3 months; afterwards, all participants received 4 mg or 9 mg following Extension-phase randomization. Overlap-weighted propensity score weighting was performed using Enroll-HD, 2CARE and CREST-E datasets (Month 3: n=21, Month 6: n=180, Month 9: n=588, Month 12: n=3569, Month 15: n=1337).

Note: The Month 15 decline in participants partly reflects study design, as the 12-month Extension period caps SKY-0515 exposure at 12 months for the participants who initially received 3 months of placebo. The primary analysis includes all eligible participants with an available Month 15 cUHDRS assessment. Per the study’s statistical analysis plan, a small number of participant-timepoints were excluded following a qualifying intercurrent event — onset of an unrelated medical condition, initiation of a medication that could confound assessment of treatment effect, or a change in background Huntington’s disease therapeutic intervention.